ClinicalTrials.gg
Active, not recruitingNCT06282159MAGICUpdated Jul 27, 2026

A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)

A Phase 2 interventional study of Claseprubart and Placebo in Myasthenia Gravis, Generalized, sponsored by Dianthus Therapeutics. Active, not recruiting at 56 sites in 14 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-27.

Sponsored by Dianthus Therapeutics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 144 studies in Myasthenia Gravis with a site in United States — 53 open to participants now, 73 under way, 25 of them phase 3. Myasthenia Gravis · United States.

Enrollment
49th of 108
65 · median 56
Started
2024
with 22 others
Phase 2
26 of 144
5 open now
Primary completion
2025-07
later than 7 of 72 live
Registered
93rd of 144
by date

Among the 144 studies in Myasthenia Gravis with a site in United States, this one is the 49th largest by enrollment of the 108 interventional ones that give a count, is one of 23 that started in 2024, is one of 26 in phase 2, reaches primary completion later than 7 of the 72 other live ones, and was the 93rd registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 144 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

53 of the 144 studies in Myasthenia Gravis with a site in United States are open now. Recruiting first, the newest first:

48 more — sign in →

All 53 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 144 studies in Myasthenia Gravis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this Phase 2 study is to evaluate the safety, tolerability, pharmacometrics, and efficacy of DNTH103 in participants with generalized myasthenia gravis (gMG).

Read the detailed description

The study includes the following periods:

  • Screening (up to 10 weeks)
  • Randomized, blinded, controlled treatment (RCT) period (13 weeks)
  • Open-label extension (OLE) period (optional) for eligible participants (104 weeks)
  • Safety follow-up (SFU) (40 weeks)
03

Conditions studied

  • Myasthenia Gravis, Generalized

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must have given written before any study-related activities are carried out.
  2. Adult males and females, 18 to 75 years of age (inclusive) at Screening.
  3. Weight range between 40-120 kg at Screening.
  4. Diagnosis of gMG by the following tests:

    Acetylcholine receptor antibody (AChR Ab) positive, and

    One of the following:

    i. History of abnormal neuromuscular transmission test; ii. History of positive anticholinesterase test; iii. Clinical response to acetylcholinesterase inhibitors.

  5. Myasthenia Gravis Foundation of America (MGFA) Class II-Iva
  6. Myasthenia Gravis Activities of Daily Living (MG-ADL) score of 6 or more
  7. Vaccination against N. meningitidis with the quadrivalent meningococcal vaccine, and where available, meningococcal serotype B vaccine within 3 years prior to, or at the time of, initiating study drug.
  8. Female participants must:

    Be of non-, or if of childbearing potential, must agree not to donate ova, not to attempt to become pregnant and, if engaging in sexual intercourse with a male partner, must agree to use a highly effective method of .

  9. Male participants must be surgically sterile for at least 90 days prior to screening or agree not to donate sperm

Exclusion criteria

Exclusion Criteria:

  1. History or presence of significant medical/surgical condition including any acute illness or major surgery considered to be
  2. Prior history (at any time) of N. meningitidis infection.
  3. Positive test results for active (HIV-1 or HIV-2), surface antigen (HBsAg), or virus (HCV) antibodies during Screening.
  4. Any thymic surgery/ within 1 year of Screening.
  5. Any known or untreated thymoma.
  6. Any history of thymic carcinoma or thymic .
  7. Concurrent or previous use of the following medication within the time periods specified below.

    1. Rituximab within 6 months (180 days) prior to randomization (Day 1);
    2. Intravenous immunoglobulin (IVIg) and plasma exchange (PLEX) within 4 weeks (28 days) prior to randomization (Day 1).
  8. Participation in another clinical study of an drug within 90 days or 5 half-lives of the investigational agent.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
65 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Experimental
    Claseprubart 300 mg Q2W

    Drug: Claseprubart

  • Experimental
    Claseprubart 600 mg Q2W

    Drug: Claseprubart

Interventions

  • Day 1: IV loading dose Week 1 to Week 11: Claseprubart administered SC every 2 weeks

    Also known as: DNTH103

  • DrugPlacebo

    Day 1: IV infusion of placebo Week 1 to Week 11: placebo administered SC every 2 weeks

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (SAEs)

    Number of participants with TEAEs and treatment-emergent SAEs will be reported.

    Time frame: Baseline (Day 1) to Week 13

Secondary outcomes

  1. Change from Baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) Scale Score

    The MG-ADL score is an 8-item patient reported outcome (PRO) instrument. The MG-ADL targets symptoms of disability across ocular, bulbar, respiratory, and axial symptoms. The item responses are scored from 0 to 3, and the total score of the MG-ADL is the sum of the 8 items and ranges from 0 to 24, with a higher score indicating more disability.

    Time frame: Baseline (Day 1) to Week 13

  2. Change from Baseline in Quantitative Myasthenia Gravis (QMG) Scale Score

    The QMG is a clinician-reported assessment to evaluate muscle strength. The QMG consists of 13 items that measure endurance or fatiguability, with each item having a possible score that ranges from 0 - 3. The total possible QMG scores range from 0 - 39, with a higher score indicating greater disease burden.

    Time frame: Baseline (Day 1) to Week 13

  3. Change from Baseline to Week 13 in Myasthenia Gravis Composite (MGC) Scale Score

    The MGC is a validated assessment tool for measuring clinical status of participants with MG. The range of total MGC score is 0 to 50, with higher scores indicating more severe disease. A clinically meaningful improvement is reflected by a 3-point improvement in MGC score. The MGC assesses 10 important functional areas most frequently affected by MG and the scales are weighted for clinical significance that incorporates patient-reported outcomes.

    Time frame: Baseline (Day 1) to Week 13

  4. Incidence of TEAEs and Treatment-Emergent SAEs

    Number of participants with TEAEs and treatment-emergent SAEs will be reported.

    Time frame: Through OLE completion, an average of 117 weeks

  5. Serum Concentrations of Claseprubart

    Blood samples will be collected for measurement of serum concentrations of claseprubart at various timepoints both pre- and post-dose.

    Time frame: Baseline (Day 1) through end of SFU, for a maximum of 197 weeks

  6. Change from Baseline in Complement Total Blood Test (CH50)

    Blood samples will be collected to determine changes in CH50 at various timepoints.

    Time frame: Baseline (Day 1) through end of SFU, for a maximum of 197 weeks

  7. Incidence and Titer of Antidrug Antibody (ADAs) Against Claseprubart

    Blood samples will be collected to measure ADA against claseprubart at various timepoints.

    Time frame: Baseline (Day 1) through end of SFU, for a maximum of 197 weeks

07

Study locations

56 sites
  • Clinical Study Site
    Phoenix, Arizona 85028, United States
  • Clinical Study Site
    Irvine, California 92868, United States
  • Clinical Study Site
    Stamford, Connecticut 06905, United States
  • Clinical Study Site
    Boca Raton, Florida 33487, United States
  • Clinical Study Site
    Bradenton, Florida 34205, United States
  • Clinical Study Site
    Maitland, Florida 32751, United States
  • Clincal Study Site
    Tampa, Florida 33620, United States
  • Clinical Study Site
    O'Fallon, Illinois 62269, United States
  • Clinical Study Site
    Kansas City, Kansas 66103, United States
  • Clinical Study Site
    Lexington, Kentucky 40503, United States
  • Clinical Study Site
    Boston, Massachusetts 02215, United States
  • Clinical Study Site
    East Lansing, Michigan 48824, United States
  • Clinical Study Site
    Columbia, Missouri 65212, United States
  • Clinical Study Site
    Cincinnati, Ohio 45219, United States
  • Clinical Study Site
    Columbus, Ohio 43221, United States
  • Clinical Study Site
    Dallas, Texas 75206, United States
  • Clinical Study Site
    Dallas, Texas 75243, United States
  • Clinical Study Site #2
    Houston, Texas 77030, United States
  • Clinical Study Site
    Houston, Texas 77030, United States
  • Clinical Study Site
    Lubbock, Texas 79414, United States
  • Clinical Study Site
    Richmond, Virginia 23219, United States
  • Clinical Study Site
    San Miguel de Tucumán, Tucumán Province T4000, Argentina
  • Clinical Study Site
    Buenos Aires, 20/11/1902, Argentina
  • Clinical Study Site
    Buenos Aires, C1012AAR, Argentina
  • Clinical Study Site
    Buenos Aires, C1015ABR, Argentina
  • Clinical Study Site
    Córdoba, X5004CDT, Argentina
  • Clinical Study Site
    Rosario, 2000, Argentina
  • Clinical Study Site
    London, Ontario N6A 5W9, Canada
  • Clinical Study Site
    Ostrava, 70852, Czechia
  • Clinical Study Site
    Copenhagen, 02100, Denmark
  • Clinical Study Site
    Bordeaux, 33076, France
  • Clinical Study Site
    Nice, 06001, France
  • Clinical Study Site
    Strasbourg, 67000, France
  • Clinical Study Site
    Haifa, 3109601, Israel
  • Clinical Study Site
    Ramat Gan, Israel
  • Clinical Study Site
    Safed, 13100, Israel
  • Clinical Study Site
    Milan, 20133, Italy
  • Clinical Study Site
    Naples, 80131, Italy
  • Clinical Study Site
    Pisa, 56126, Italy
  • Clinical Study Site
    Rome, 00168, Italy
  • Clinical Study Site
    Rome, 00189, Italy
  • Clinical Study Site
    Amsterdam, Netherlands
  • Clinical Study Site
    Skopje, 1000, North Macedonia
  • Clinical Study Site
    Bergen, 5021, Norway
  • Clinical Study Site
    Bydgoszcz, 85-065, Poland
  • Clinical Study Site
    Katowice, 40123, Poland
  • Clinical Study Site
    Krakow, 31-202, Poland
  • Clinical Study Site
    Krakow, 31-503, Poland
  • Clinical Study Site
    Lublin, 20-093, Poland
  • Clinical Study Site
    Warsaw, 01-684, Poland
  • Clinical Study Site
    Warsaw, 02-657, Poland
  • Clinical Study Site
    Belgrade, 11000, Serbia
  • Clinical Study Site
    Kragujevac, 34000, Serbia
  • Clinical Study Site
    Niš, 18000, Serbia
  • Clinical Study Site
    Novi Sad, 21000, Serbia
  • Clinical Study Site
    Malmö, Sweden
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Jul 2025, 17 months.

Of 22 phase 2 interventional studies under Myasthenia Gravis, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 30. This study's 17 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2023
First posted
Feb 28, 2024
StartActual
Feb 23, 2024
Primary completionActual
Jul 28, 2025
CompletionEst.
Oct 2028
Results delay requested
Jul 23, 2026
Last update
Jul 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06282159
Lead sponsor
Dianthus Therapeutics
Responsible party
Sponsor
First posted
Feb 28, 2024
Start date
Feb 23, 2024
Primary completion
Jul 28, 2025
Completion
Oct 2028 (estimated)
Last update
Jul 27, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Claseprubart

Start the discussion